<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR314.html">Part 314
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 314.54  Procedure for submission of an application requiring  from, a listed drug.
                            </h3>
                            <p class="depth1"><em>(a)</em> The act does not permit approval of an abbreviated new drug  application for a new indication, nor does it permit approval of other  changes in a listed drug if investigations, other than bioavailability  or bioequivalence studies, are essential to the approval of the change.  Any person seeking approval of a drug product that represents a  modification of a listed drug (e.g., a new indication or new dosage  form) and for which investigations, other than bioavailability or  bioequivalence studies, are essential to the approval of the changes  may, except as provided in paragraph (b) of this section, submit a  505(b)(2) application. This application need contain only that  information needed to support the modification(s) of the listed drug.</p><p class="depth2"><em>(1)</em> The applicant shall submit a complete archival copy of the  application that contains the following:</p><p class="depth3"><em>(i)</em> The information required under Sec. 314.50(a), (b), (c),  (d)(1), (d)(3), (e), and (g), except that Sec. 314.50(d)(1)(ii)(c)  shall contain the proposed or actual master production record, including  a description of the equipment, to be used for the manufacture of a  commercial lot of the drug product.</p><p class="depth3"><em>(ii)</em> The information required under Sec. 314.50 (d)(2), (d)(4) (if  an anti-infective drug), (d)(5), (d)(6), and (f) as needed to support  the safety and effectiveness of the drug product.</p><p class="depth3"><em>(iii)</em> Identification of the listed drug for which FDA has made a  finding of safety and effectiveness and on which finding the applicant  relies in seeking approval of its proposed drug product by established  name, if any, proprietary name, dosage form, strength, route of  administration, name of listed drug's application holder, and listed  drug's approved application number.</p><p class="depth3"><em>(iv)</em> If the applicant is seeking approval only for a new indication  and not for the indications approved for the listed drug on which the  applicant relies, a certification so stating.</p><p class="depth3"><em>(v)</em> Any patent information required under section 505(b)(1) of the  act with respect to any patent which claims the drug for which approval  is sought or a method of using such drug and to which a claim of patent  infringement could reasonably be asserted if a person not licensed by  the owner of the patent engaged in the manufacture, use, or sale of the  drug product.</p><p class="depth3"><em>(vi)</em> Any patent certification or statement required under section  505(b)(2) of the act with respect to any relevant patents that claim the  listed drug or   that claim any other drugs on which investigations relied on by the  applicant for approval of the application were conducted, or that claim  a use for the listed or other drug.</p><p class="depth3"><em>(vii)</em> If the applicant believes the change for which it is seeking  approval is entitled to a period of exclusivity, the information  required under Sec. 314.50(j).</p><p class="depth2"><em>(2)</em>, (d)(4), (d)(5), (d)(6), and (f) when needed to support the  modification. Each of the technical sections in the review copy is  required to be separately bound with a copy of the information required  under Sec. 314.50 (a), (b), and (c) and a copy of the proposed  labeling.</p><p class="depth2"><em>(3)</em> The information required by Sec. 314.50 (d)(2), (d)(4) (if an  anti-infective drug), (d)(5), (d)(6), and (f) for the listed drug on  which the applicant relies shall be satisfied by reference to the listed  drug under paragraph (a)(1)(iii) of this section.</p><p class="depth2"><em>(4)</em> The applicant shall submit a field copy of the application that  contains the technical section described in Sec. 314.50(d)(1), a copy  of the information required under Sec. 314.50(a) and (c), and  certification that the field copy is a true copy of the technical  section described in Sec. 314.50(d)(1) contained in the archival and  review copies of the application.</p><p class="depth1"><em>(b)</em> An application may not be submitted under this section for a  drug product whose only difference from the reference listed drug is  that:</p><p class="depth2"><em>(1)</em> The extent to which its active ingredient(s) is absorbed or  otherwise made available to the site of action is less than that of the  reference listed drug; or</p><p class="depth2"><em>(2)</em> The rate at which its active ingredient(s) is absorbed or  otherwise made available to the site of action is unintentionally less  than that of the reference listed drug.  [57 FR 17982, Apr. 28, 1992; 57 FR 61612, Dec. 28, 1992, as amended at  58 FR 47351, Sept. 8, 1993; 59 FR 50364, Oct. 3, 1994]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
